Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics, Jain Foundation Ink Stem Cell Line Deal

NEW YORK (GenomeWeb News) – Cellular Dynamics will create five induced pluripotent stem cell lines from patients with muscular dystrophy for the Jain Foundation under a master service agreement announced today.

The partners noted that there are currently no effective treatments for the genetic disorder, so "establishing model iSPC lines is an important step toward developing new drugs and therapies for these patients."

Madison, Wis.-based CDI said that it will use its MyCell Products line to create iSPC lines derived from Limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi muscular dystrophy 1 patients. Terms of the agreement were not disclosed.

"iPSC technology promises to provide a path to better understand these devastating genetic diseases so that researchers can develop therapies," Plavi Mittal, president and CEO of the Jain Foundation. "CDI's ability to make iPSCs at high quality and purity from any individual, including LGMD2B patients, will provide scientists new tools to understand and address these debilitating forms of muscular dystrophy."

The Seattle-based Jain Foundation is a nonprofit organization focused on supporting research into cures for muscular dystrophy.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more